Tractatenblad 2016, 3

66 (1989) Nr. 22

A. TITEL

Overeenkomst ter bestrijding van doping;

(met Bijlage)

Straatsburg, 16 november 1989

B. TEKST

De Engelse en de Franse tekst van de Overeenkomst, met Bijlage, zijn geplaatst in Trb. 1991, 8.

Voor correcties in de Engelse tekst van dat Tractatenblad, zie Trb. 2014, 162 en Trb. 2015, 87.

Voor wijzigingen van de tekst van de Bijlage, zie rubriek J van Trb. 1995, 114, Trb. 1996, 284, Trb. 1997, 44, Trb. 1997, 244, Trb. 1998, 104, Trb. 2001, 98, Trb. 2001, 185, Trb. 2003, 40, Trb. 2004, 194 en rubriek B van Trb. 2005, 67, Trb. 2006, 33, Trb. 2008, 83, Trb. 2009, 24, Trb. 2010, 80, Trb. 2011, 19, Trb. 2011, 274, Trb. 2012, 243, Trb. 2014, 21, Trb. 2014, 162, Trb. 2015, 87.

Voor enkele correcties, zie Trb. 2008, 83, Trb. 2009, 24 en Trb. 2015, 87.

---

De Commissie van Toezicht heeft op 9 december 2015, op grond van artikel 11, eerste lid, onder b, van de Overeenkomst, te Straatsburg een wijziging van de Bijlage aangenomen. De Engelse tekst¹⁾ van de wijziging luidt als volgt:

The 2016 prohibited list

World Anti-Doping Code

Date of entry into force: 1 January 2016

In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S.4.4, S.4.5, S6.a, and Prohibited Methods M1, M2 and M3.

Substances and methods prohibited at all times (in- and out-of-competition)

Prohibited substances

S0. Non-approved substances

Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

S1. Anabolic agents

Anabolic agents are prohibited.

• 1. Anabolic Androgenic Steroids (AAS)

  • a. Exogenous²⁾ AAS, including:

    1-Androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-Androstenedione (5α-androst-1-ene-3,17-dione); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); 19-Norandrostenedione (estr-4-ene-3,17-dione); Bolandiol (estr-4-ene-3β,17β-diol); Bolasterone; Boldenone; Boldione (androsta-1,4-diene-3,17-dione); Calusterone; Clostebol; Danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en-20-yn-17α-ol); Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol); Drostanolone; Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone; Formebolone; Furazabol (17α-methyl [1,2,5]oxadiazolo[3’,4’:2,3]-5α-androstan-17β-ol); Gestrinone; Mestanolone; Mesterolone; Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); Metenolone; Methandriol;

    Methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one); Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one); Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); Methyltestosterone; Metribolone (methyltrienolone, 17β-hydroxy-17α-methylestra-4,9,11-trien-3-one); Mibolerone; Nandrolone; Norboletone; Norclostebol; Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5α-androstane); Quinbolone; Stanozolol; Stenbolone; Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one); Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one);

    and other substances with a similar chemical structure or similar biological effect(s).

  • b. Endogenous³⁾ AAS when administered exogenously:

    Androstenediol (androst-5-ene-3β,17β-diol); Androstenedione (androst-4-ene-3,17-dione); Dihydrotestosterone (17β-hydroxy-5α-androstan-3-one) ; Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); Testosterone;

    and their metabolites and isomers, including but not limited to:

    3β-Hydroxy-5α-androstan-17-one; 5α-Androstane-3α,17α-diol; 5α-Androstane-3α,17β-diol; 5α-Androstane-3β,17α-diol; 5α-Androstane-3β,17β-diol; 5β-Androstane-3α,17β-diol; 7α-Hydroxy-DHEA; 7β-Hydroxy-DHEA; 4-Androstenediol (androst-4-ene-3β,17β-diol); 5-Androstenedione (androst-5-ene-3,17-dione); 7-Keto-DHEA; 19-Norandrosterone; 19-Noretiocholanolone; Androst-4-ene-3α,17α-diol; Androst-4-ene-3α,17β-diol; Androst-4-ene-3β,17α-diol; Androst-5-ene-3α,17α-diol; Androst-5-ene-3α,17β-diol; Androst-5-ene-3β,17α-diol; Androsterone; Epi-dihydrotestosterone; Epitestosterone; Etiocholanolone.

• 2. Other Anabolic Agents, including but not limited to:

  Clenbuterol, selective androgen receptor modulators (SARMs, e.g. andarine and ostarine), tibolone, zeranol and zilpaterol.

S2. Peptide hormones, growth factors, related substances and mimetics

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

• 1. Erythropoietin-Receptor agonists:

  • 1.1. Erythropoiesis-Stimulating Agents (ESAs) including e.g. Darbepoietin (dEPO); Erythropoietins (EPO); EPO-Fc; EPO-mimetic peptides (EMP), e.g. CNTO 530 and peginesatide; methoxy polyethylene glycol-epoetin beta (CERA).

  • 1.2. Non-erythropoietic EPO-Receptor agonists, e.g. ARA-290, asialo EPO; carbamylated EPO.

• 2. Hypoxia-inducible factor (HIF) stabilizers, e.g. cobalt and FG-4592; and HIF activators, e.g. argon, xenon;

• 3. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors, e.g. buserelin, gonadorelin and leuprorelin, in males;

• 4. Corticotrophins and their releasing factors, e.g corticorelin;

• 5. Growth Hormone (GH) and its releasing factors including Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin and ipamorelin; GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-6, hexarelin and pralmorelin (GHRP-2).

Additional prohibited growth factors:

Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

S3. Beta-2 agonists

All beta-2 agonists, including all optical isomers, e.g. d- and l- where relevant, are prohibited.

Except:

• Inhaled salbutamol (maximum 1600 micrograms over 24 hours);

• Inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours); and

• Inhaled salmeterol in accordance with the manufacturers” recommended therapeutic regimen.

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.

S4. Hormone and metabolic modulators

The following hormone and metabolic modulators are prohibited:

• 1. Aromatase inhibitors including, but not limited to: 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Exemestane; Formestane; Letrozole; Testolactone.

• 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: Raloxifene; Tamoxifen; Toremifene.

• 3. Other anti-estrogenic substances including, but not limited to: Clomiphene; Cyclofenil; Fulvestrant.

• 4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors.

• 5. Metabolic modulators:

  • 5.1. Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR; and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. GW 1516;

  • 5.2. Insulins and insulin-mimetics;

  • 5.3. Meldonium;

  • 5.4. Trimetazidine.

S5. Diuretics and masking agents

The following diuretics and masking agents are prohibited, as are other substances with a similar chemical structure or similar biological effect(s).

Including, but not limited to:

• Desmopressin; probenecid; plasma expanders, e.g. glycerol and intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol.

• Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan.

Except:

• Drospirenone; pamabrom; and ophtalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide).

• Local administration of felypressin in dental anaesthesia.

The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding unless the Athlete has an approved TUE for that substance in addition to the one granted for the diuretic or masking agent.

Prohibited methods

M1. Manipulation of blood and blood components

The following are prohibited:

• 1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.

• 2. Artificially enhancing the uptake, transport or delivery of oxygen.

  Including, but not limited to:

  Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen.

• 3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

M2. Chemical and physical manipulation

The following are prohibited:

• 1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control.

  Including, but not limited to:

  Urine substitution and/or adulteration, e.g. proteases.

• 2. Intravenous infusions and/or injections of more than 50 mL per 6 hour period except for those legitimately received in the course of hospital admissions, surgical procedures or clinical investigations.

M3. Gene doping

The following, with the potential to enhance sport performance, are prohibited:

• 1. The transfer of polymers of nucleic acids or nucleic acid analogues;

• 2. The use of normal or genetically modified cells.

Substances and methods prohibited in-competition

In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited In-Competition:

Prohibited substances⁴⁾

S6. Stimulants

All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited.

Stimulants include:

• a: Non-Specified Stimulants:

  Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex; Mefenorex; Mephentermine; Mesocarb; Metamfetamine(d-); p-Methylamphetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine. Prolintane.

  A stimulant not expressly listed in this section is a Specified Substance.

• b: Specified Stimulants:

  Including, but not limited to:

  Benzfetamine; Cathine⁵⁾; Cathinone and its analogues, e.g. mephedrone, methedrone, and α - pyrrolidinovalerophenone; Dimethylamphetamine; Ephedrine⁶⁾; Epinephrine⁷⁾ (adrenaline); Etamivan; Etilamfetamine; Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene; Levmetamfetamine; Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine⁸⁾; Methylhexaneamine (dimethylpentylamine); Methylphenidate; Nikethamide; Norfenefrine; Octopamine; Oxilofrine (methylsynephrine); Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine⁹⁾; Selegiline; Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine), Tuaminoheptane;

  and other substances with a similar chemical structure or similar biological effect(s).

Except:

• Clonidine

• Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2016 Monitoring Program¹⁰⁾.

S7. Narcotics

Prohibited:

Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone; Morphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine.

S8. Cannabinoids

Prohibited:

• Natural, e.g. cannabis, hashish and marijuana, or synthetic Δ9-tetrahydrocannabinol (THC).

• Cannabimimetics, e.g. “Spice”, JWH-018, JWH-073, HU-210.

S9. Glucocorticoids

All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.

Substances prohibited in particular sports

P1. Alcohol

Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10 g/L.

• Air Sports (FAI)

• Archery (WA)

• Automobile (FIA)

• Powerboating (UIM)

P2. Beta-blockers

Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated.

• Archery (WA) ¹¹⁾

• Automobile (FIA)

• Billiards (all disciplines) (WCBS)

• Darts (WDF)

• Golf (IGF)

• Shooting (ISSF, IPC)¹²⁾

• Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air

• Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without fins,

Including, but not limited to:

Acebutolol; Alprenolol; Atenolol; Betaxolol; Bisoprolol; Bunolol; Carteolol; Carvedilol; Celiprolol; Esmolol; Labetalol; Levobunolol; Metipranolol; Metoprolol; Nadolol; Oxprenolol; Pindolol; Propranolol; Sotalol; Timolol.

---

C. VERTALING

Zie Trb. 1991, 8.

Voor correcties, zie Trb. 2014, 162.

D. PARLEMENT

Zie Trb. 1995, 114.

E. PARTIJGEGEVENS

Zie Trb. 1991, 8, rubriek F en rubriek H van Trb. 1995, 114 en, laatstelijk, Trb. 2014, 21.

G. INWERKINGTREDING

Zie Trb. 1991, 8, Trb. 1995, 114, rubriek J van Trb. 1996, 284, Trb. 1997, 244, Trb. 1998, 104, Trb. 2001, 98, Trb. 2001, 185, Trb. 2003, 40 en Trb. 2004, 194, en rubriek G van Trb. 2005, 67, Trb. 2006, 33, Trb. 2008, 83, Trb. 2009, 24, Trb. 2010, 80, Trb. 2011, 19, Trb. 2011, 274, Trb. 2012, 243, Trb. 2014, 21, Trb. 2014, 162 en Trb. 2015, 87.

---

De wijziging van 9 december 2015 van de Bijlage bij de Overeenkomst zal op 1 januari 2016 in werking treden voor alle partijen bij de Overeenkomst, waaronder het Koninkrijk der Nederlanden.

Wat betreft het Koninkrijk der Nederlanden, geldt de wijziging van de Bijlage, evenals de Overeenkomst, voor Nederland (het Europese deel en het Caribische deel), Curaçao en Sint-Maarten.

Koninkrijk der Nederlanden

Land	Voorlopige toepassing	In werking	Terugwerkende kracht	Buiten werking
Nederland (in Europa)		01-06-1995
Nederland (Bonaire)		10-10-2010
Nederland (Sint Eustatius)		10-10-2010
Nederland (Saba)		10-10-2010
Aruba
Curaçao		10-10-2010
Sint Maarten		10-10-2010
De Overeenkomst, met Bijlage, gold sinds 01-01-2009 voor de Nederlandse Antillen.

J. VERWIJZINGEN

Zie Trb. 1991, 8, Trb. 1995, 114, Trb. 1996, 284, Trb. 1997, 44, Trb. 2004, 194, Trb. 2006, 33, Trb. 2008, 83, Trb. 2009, 24, Trb. 2010, 80, Trb. 2011, 274, Trb. 2012, 243, Trb. 2014, 21, Trb. 2014, 162 en Trb. 2015, 87.

Verbanden

Titel	:	Internationaal Verdrag tegen doping in de sport; Parijs, 19 oktober 2005
Laatste Trb.	:	Trb. 2016, 4

Overige verwijzingen

Titel	:	Statuut van de Raad van Europa; Londen, 5 mei 1949
Laatste Trb.	:	Trb. 2015, 102

---

In overeenstemming met artikel 19, tweede lid, van de Rijkswet goedkeuring en bekendmaking verdragen heeft de Minister van Buitenlandse Zaken bepaald dat de wijziging van 9 december 2015 van de Bijlage bij de Overeenkomst zal zijn bekendgemaakt in Nederland (het Europese en het Caribische deel), Curaçao en Sint Maarten op de dag na de datum van uitgifte van dit Tractatenblad.

Uitgegeven de twintigste januari 2016.

De Minister van Buitenlandse Zaken, A.G. KOENDERS

---

1) De Franse tekst is niet opgenomen.

2) “Exogenous” refers to a substance which is not ordinarily produced by the body naturally.

3) “Endogenous” refers to a substance which is ordinarily produced by the body naturally.

4) Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2016 Monitoring Program, and are not considered Prohibited Substances.

5) Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.

6) Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.

7) Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents.

8) Methylephedrine and ephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.

9) Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

10) Also prohibited Out-of-Competition

11) Also prohibited Out-of-Competition

12) Also prohibited Out-of-Competition